Opthea Limited (ASX:OPT)
0.6000
0.00 (0.00%)
Mar 14, 2025, 4:10 PM AEST
Opthea Revenue
Opthea had revenue of $149.00K USD in the half year ending December 30, 2024, a decrease of -24.39%. This brings the company's revenue in the last twelve months to $208.86K, down -46.47% year-over-year. In the fiscal year ending June 30, 2024, Opthea had annual revenue of $261.86K, down -32.03%.
Revenue (ttm)
$208.86K
Revenue Growth
-46.47%
P/S Ratio
n/a
Revenue / Employee
$6.33K
Employees
33
Market Cap
738.77M AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 261.86K | -123.42K | -32.03% |
Jun 30, 2023 | 385.28K | 186.27K | 93.60% |
Jun 30, 2022 | 199.01K | 103.44K | 108.24% |
Jun 30, 2021 | 95.56K | -5.13K | -5.09% |
Jun 30, 2020 | 100.69K | -136.12K | -57.48% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOpthea News
- 2 days ago - Pengana freezes fund redemptions as it braces for big Opthea loss - The Australian Financial Review
- 3 days ago - ASX 200 LIVE: Donald Trump eyeing copper tariffs; February CPI below forecasts; sharemarket rises. - The Australian Financial Review
- 4 days ago - Regal’s listed funds slash value of biotech Opthea by two-thirds - The Australian Financial Review
- 4 days ago - Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty - Benzinga
- 5 days ago - Investors fret over clinical trial failure’s hit on Regal funds - The Australian Financial Review
- 5 days ago - Opthea Announces COAST Phase 3 Trial Topline Results - GlobeNewsWire
- 5 days ago - ASX 200 LIVE: UBS upgrades FMG; OPT in crisis talks after drug trial fails, shares suspended; sharemarket falls. - The Australian Financial Review
- 12 days ago - It’s Phil King’s Regal against the shorts at biotech play Opthea - The Australian Financial Review